Citigroup
CLDI icon

Citigroup’s Calidi Biotherapeutics CLDI Stock Holding History

Citigroup’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$781 Buy
287
+286
+28,600% +$924 ﹤0.01% 5428
2026
Q1 		$3 Buy
+1
New +$12 ﹤0.01% 5804
2025
Q4 		– Hold
0
– – – 5960

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citigroup's CLDI Position: Q2 2026 in Review

Citigroup increased its Calidi Biotherapeutics (CLDI) stake by 28,600% in Q2 2026, buying an estimated $924 and bringing the position to 287 shares worth $781. The position accounts for ﹤0.01% of the portfolio, ranked #5428.

Citigroup first reported a position in CLDI in Q1 2026 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Citigroup held 287 shares of Calidi Biotherapeutics worth $781 as of Q2 2026.
  • Citigroup bought 286 Calidi Biotherapeutics shares in Q2 2026, an estimated $924.
  • Calidi Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5428 holding.
  • Citigroup first reported a position in Calidi Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.